ACR Appropriateness Criteria ® Resectable Pancreatic Cancer

William E. Jones, W. Waren Suh, May Abdel-Wahab, Ross A. Abrams, Nilofer Azad, Prajnan Das, Jadranka Dragovic, Karyn A. Goodman, Salma K. Jabbour, Andre A. Konski, Albert C. Koong, Rachit Kumar, Percy Lee, Timothy M. Pawlik, William Small, Joseph M. Herman

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number2
StatePublished - 2017


  • Appropriateness criteria
  • adjuvant therapy
  • resectable pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ACR Appropriateness Criteria ® Resectable Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this